An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: ACP-196 (acalabrutinib)

Sponsor

Acerta Pharma BV